The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 02, 2019
Filed:
May. 29, 2015
Applicant:
The Johns Hopkins University, Baltimore, MD (US);
Inventors:
Hans Tomas Bjornsson, Baltimore, MD (US);
Harry Dietz, Towson, MD (US);
Assignee:
The Johns Hopkins University, Baltimore, MD (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); A01K 67/027 (2006.01); G01N 33/542 (2006.01); G01N 33/58 (2006.01); A61K 31/165 (2006.01); A61K 31/167 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 14/47 (2013.01); A01K 67/0275 (2013.01); A01K 67/0276 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); G01N 33/5008 (2013.01); G01N 33/542 (2013.01); G01N 33/582 (2013.01); G01N 33/6893 (2013.01); A01K 2217/072 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0356 (2013.01); C07K 2319/09 (2013.01); C07K 2319/60 (2013.01); C07K 2319/61 (2013.01); C07K 2319/90 (2013.01); C07K 2319/91 (2013.01); C07K 2319/915 (2013.01); C07K 2319/95 (2013.01); G01N 2500/04 (2013.01); G01N 2500/10 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract
Non-FRET-based fusion protein reporter molecules are provided that can be used to monitor histone modifications in living cells. Transgenic animals, particularly non-human mammals, whose genomes comprise an expression cassette encoding a non-FRET-based fusion protein reporter, are also provided. Methods of using the fusion reporter molecules for diagnosing histone-modification-associated disorders and to identify candidate pharmaceutical agents that effect histone modification in cells and tissues are also provided.